|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||46.96 kg/mol g·mol−1|
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.
One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point. The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.
These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.
- World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Lampalizumab, American Medical Association.
- "Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration". www.roche.com. Retrieved 2017-09-14.
- "Statement on Chroma Study". www.roche.com. Retrieved 2017-11-10.
- Dolgin, E (9 November 2017). "Age-related macular degeneration foils drugmakers". Nature Biotechnology. 35 (11): 1000–1001. doi:10.1038/nbt1117-1000. PMID 29121027.
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|